Literature DB >> 26179982

Candida bracarensis: Evaluation of Virulence Factors and its Tolerance to Amphotericin B and Fluconazole.

André Moreira1, Sónia Silva2, Cláudia Botelho1, Paula Sampaio3, Célia Pais3, Mariana Henriques1.   

Abstract

Candida bracarensis is an uncommon Candida species found during an epidemiological study of candidiasis performed in Braga, Portugal. Initially, it was identified as C. glabrata, but recently detailed analyses pointed out their differences. So, little information is still available about C. bracarensis virulence factors and antifungal susceptibilities. Therefore, the main goal of this work is to evaluate the ability of C. bracarensis to form biofilms, to produce hydrolytic enzymes (proteases, phospholipases and hemolysins), as well as its susceptibility to amphotericin B and fluconazole. It was shown, for the first time, that all C. bracarensis strains were able to form biofilms and display proteinase and hemolytic activities. Moreover, although planktonic cells presented antifungal susceptibility, amphotericin B and fluconazole were unable to inhibit biofilm formation and eradicate pre-formed biofilms. Due to the propensity of C. bracarensis to display antifungal resistance and virulence attributes, the control of these emerging pathogens is recommended.

Entities:  

Keywords:  Amphotericin B; Antifungal resistance; Candida bracarensis; Fluconazole; Virulence factors

Mesh:

Substances:

Year:  2015        PMID: 26179982     DOI: 10.1007/s11046-015-9925-y

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  30 in total

1.  Silicone colonization by non-Candida albicans Candida species in the presence of urine.

Authors:  Sónia Silva; Melyssa Negri; Mariana Henriques; Rosário Oliveira; David Williams; Joana Azeredo
Journal:  J Med Microbiol       Date:  2010-03-18       Impact factor: 2.472

2.  The epidemiology of hematogenous candidiasis caused by different Candida species.

Authors:  D Abi-Said; E Anaissie; O Uzun; I Raad; H Pinzcowski; S Vartivarian
Journal:  Clin Infect Dis       Date:  1997-06       Impact factor: 9.079

Review 3.  Experimental oral candidiasis in animal models.

Authors:  Y H Samaranayake; L P Samaranayake
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

4.  Phospholipase B enzyme expression is not associated with other virulence attributes in Candida albicans isolates from patients with human immunodeficiency virus infection.

Authors:  Y H Samaranayake; R S Dassanayake; J Ams Jayatilake; B Pk Cheung; J Yy Yau; K Ws Yeung; L P Samaranayake
Journal:  J Med Microbiol       Date:  2005-06       Impact factor: 2.472

5.  International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program.

Authors:  M A Pfaller; D J Diekema; R N Jones; H S Sader; A C Fluit; R J Hollis; S A Messer
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

6.  Penetration of Candida biofilms by antifungal agents.

Authors:  Mohammed A Al-Fattani; L Julia Douglas
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  Comparison of multiple methods for quantification of microbial biofilms grown in microtiter plates.

Authors:  Elke Peeters; Hans J Nelis; Tom Coenye
Journal:  J Microbiol Methods       Date:  2007-11-21       Impact factor: 2.363

Review 8.  Identification of Candida species in the clinical laboratory: a review of conventional, commercial, and molecular techniques.

Authors:  K H Neppelenbroek; R S Seó; V M Urban; S Silva; L N Dovigo; J H Jorge; N H Campanha
Journal:  Oral Dis       Date:  2013-05-16       Impact factor: 3.511

9.  Plate method for detection of phospholipase activity in Candida albicans.

Authors:  M F Price; I D Wilkinson; L O Gentry
Journal:  Sabouraudia       Date:  1982-03

10.  Identification of Candida nivariensis and Candida bracarensis in a large global collection of Candida glabrata isolates: comparison to the literature.

Authors:  Shawn R Lockhart; Shawn A Messer; Michael Gherna; Justin A Bishop; William G Merz; Michael A Pfaller; Daniel J Diekema
Journal:  J Clin Microbiol       Date:  2009-02-04       Impact factor: 5.948

View more
  4 in total

1.  Caenorhabditis elegans as a Model System To Assess Candida glabrata, Candida nivariensis, and Candida bracarensis Virulence and Antifungal Efficacy.

Authors:  Ainara Hernando-Ortiz; Estibaliz Mateo; Marcelo Ortega-Riveros; Iker De-la-Pinta; Guillermo Quindós; Elena Eraso
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

Review 2.  How much do we know about hemolytic capability of pathogenic Candida species?

Authors:  Márcia C Furlaneto; Helena P Góes; Hugo F Perini; Renan C Dos Santos; Luciana Furlaneto-Maia
Journal:  Folia Microbiol (Praha)       Date:  2018-01-15       Impact factor: 2.099

3.  First report of Candida bracarensis in Mexico: hydrolytic enzymes and antifungal susceptibility pattern.

Authors:  Rogelio de J Treviño-Rangel; José F Espinosa-Pérez; Hiram Villanueva-Lozano; Alexandra M Montoya; Angel Andrade; Alexandro Bonifaz; Gloria M González
Journal:  Folia Microbiol (Praha)       Date:  2018-02-27       Impact factor: 2.099

Review 4.  The birth of a deadly yeast: tracing the evolutionary emergence of virulence traits in Candida glabrata.

Authors:  Toni Gabaldón; Laia Carreté
Journal:  FEMS Yeast Res       Date:  2015-12-17       Impact factor: 2.796

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.